Analysts expect that AngioDynamics, Inc. (NASDAQ:ANGO) will report earnings of $0.21 per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for AngioDynamics’ earnings, with the highest EPS estimate coming in at $0.21 and the lowest estimate coming in at $0.20. AngioDynamics posted earnings of $0.16 per share in the same quarter last year, which indicates a positive year over year growth rate of 31.3%. The firm is expected to announce its next earnings report on Thursday, January 3rd.

On average, analysts expect that AngioDynamics will report full year earnings of $0.85 per share for the current financial year. For the next year, analysts expect that the company will post earnings of $0.99 per share, with EPS estimates ranging from $0.97 to $1.01. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow AngioDynamics.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, September 27th. The medical instruments supplier reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. The business had revenue of $85.34 million during the quarter, compared to analyst estimates of $84.05 million. During the same quarter in the prior year, the company posted $0.13 earnings per share. The company’s revenue was down .1% on a year-over-year basis.

A number of research analysts recently commented on the company. BidaskClub cut AngioDynamics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 1st. Canaccord Genuity reiterated a “hold” rating and issued a $20.00 price objective on shares of AngioDynamics in a report on Thursday, July 12th. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a report on Tuesday, September 11th. Finally, Raymond James cut AngioDynamics from an “outperform” rating to a “market perform” rating in a report on Wednesday, July 11th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. AngioDynamics has an average rating of “Buy” and a consensus target price of $18.44.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Piedmont Investment Advisors LLC acquired a new position in AngioDynamics during the second quarter worth $191,000. Crossmark Global Holdings Inc. acquired a new position in AngioDynamics during the second quarter worth $205,000. Element Capital Management LLC acquired a new position in AngioDynamics during the first quarter worth $217,000. Sun Life Financial INC acquired a new position in AngioDynamics during the second quarter worth $231,000. Finally, SG Americas Securities LLC acquired a new position in AngioDynamics during the second quarter worth $336,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

ANGO traded down $0.45 during trading hours on Tuesday, reaching $20.14. The company’s stock had a trading volume of 155,090 shares, compared to its average volume of 300,906. AngioDynamics has a fifty-two week low of $15.16 and a fifty-two week high of $24.49. The stock has a market capitalization of $747.64 million, a PE ratio of 27.22 and a beta of 0.86. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.55 and a current ratio of 2.64.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

See Also: Understanding each part of a balance sheet

Get a free copy of the Zacks research report on AngioDynamics (ANGO)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with's FREE daily email newsletter.